Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of treatment with methylprednisolone on the serum levels of IL-12, IL-10 and CCL2 chemokine in patients with multiple sclerosis in relapse.
Rentzos M, Nikolaou C, Rombos A, Evangelopoulos ME, Kararizou E, Koutsis G, Zoga M, Dimitrakopoulos A, Tsoutsou A, Sfangos C. Rentzos M, et al. Among authors: evangelopoulos me. Clin Neurol Neurosurg. 2008 Dec;110(10):992-6. doi: 10.1016/j.clineuro.2008.06.005. Epub 2008 Jul 25. Clin Neurol Neurosurg. 2008. PMID: 18657352 Clinical Trial.
Proinflammatory cytokines in serum and cerebrospinal fluid of CIDP patients.
Rentzos M, Angeli AV, Rombos A, Kyrozis A, Nikolaou C, Zouvelou V, Dimitriou A, Zoga M, Evangelopoulos ME, Tsatsi A, Tsoutsou A, Evdokimidis I. Rentzos M, et al. Among authors: evangelopoulos me. Neurol Res. 2012 Nov;34(9):842-6. doi: 10.1179/1743132812Y.0000000074. Epub 2012 Sep 4. Neurol Res. 2012. PMID: 22947427
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Association of B-cell activating factor gene variants with serum anti-JCV antibody positivity in male patients with multiple sclerosis under natalizumab treatment: Implications for progressive multifocal leukoencephalopathy risk stratification.
Skarlis C, Papadopoulos V, Raftopoulou S, Mavragani CP, Evangelopoulos ME. Skarlis C, et al. Among authors: evangelopoulos me. J Neurol Sci. 2024 Jun 15;461:123046. doi: 10.1016/j.jns.2024.123046. Epub 2024 May 12. J Neurol Sci. 2024. PMID: 38761670
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.
Friedli C, Krajnc N, Hammer HN, Marti S, Zrzavy T, Evangelopoulos ME, Kapsali I, Rommer P, Berger T, Chan A, Bsteh G, Hoepner R. Friedli C, et al. Among authors: evangelopoulos me. J Cent Nerv Syst Dis. 2024 May 5;16:11795735241249644. doi: 10.1177/11795735241249644. eCollection 2024. J Cent Nerv Syst Dis. 2024. PMID: 38711956 Free PMC article.
How Early Is Early Multiple Sclerosis?
Stavropoulou De Lorenzo S, Bakirtzis C, Konstantinidou N, Kesidou E, Parissis D, Evangelopoulos ME, Elsayed D, Hamdy E, Said S, Grigoriadis N. Stavropoulou De Lorenzo S, et al. Among authors: evangelopoulos me. J Clin Med. 2023 Dec 29;13(1):214. doi: 10.3390/jcm13010214. J Clin Med. 2023. PMID: 38202221 Free PMC article. Review.
Multiple faces of multiple sclerosis in the era of highly efficient treatment modalities: Lymphopenia and switching treatment options challenges daily practice.
Vakrakou AG, Brinia ME, Alexaki A, Koumasopoulos E, Stathopoulos P, Evangelopoulos ME, Stefanis L, Stadelmann-Nessler C, Kilidireas C. Vakrakou AG, et al. Among authors: evangelopoulos me. Int Immunopharmacol. 2023 Dec;125(Pt B):111192. doi: 10.1016/j.intimp.2023.111192. Epub 2023 Nov 9. Int Immunopharmacol. 2023. PMID: 37951198 Review.
93 results